Therapy Areas: Devices
Allegro Ophthalmics Names Carlson, Colbert to the Company's Board of Directors
10 April 2019 - - US-based biopharmaceutical company Allegro Ophthalmics, LLC has appointed two new independent members, Marc Carlson and Rebecca Colbert, to the company's board of directors with Colbert serving as chairperson of the board's audit committee, the company said.

Carlson brings more than 35 years of experience commercializing products in a variety of industries and creating value for shareholders. Formerly chief customer officer of DocuSign, Carlson's expertise helped DocuSign navigate a crowded marketplace and emerge as a leader in its space.

His focus on providing measurable value to customers and shareholders alike as well as his ability to develop creative growth stories and global brands were instrumental in the commercial growth of DocuSign from a USD 50m private company to a public company with a nearly USD 10bn market capitalization over a period of seven years.

Currently chief financial officer at Vertos Medical, Inc., Colbert has more than 15 years of experience working in senior level positions for medical device companies, including in her role as vice president, customer and sales operations, US Surgical at Bausch + Lomb before joining Vertos.

As vice president of finance at eyeonics, Inc., Colbert played a significant role in the company's filing for its initial public offering and ultimate sale to Bausch + Lomb. She began her career at Deloitte as a certified public accountant.

Allegro Ophthalmics is a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases. 

Pre-clinical data suggest that risuteganib (Luminate), Allegro's lead investigational anti-integrin compound in retina, simultaneously acts on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as diabetic macular edema and intermediate dry age-related macular degeneration (intermediate dry AMD).

Risuteganib successfully completed two Phase 2 DME studies and is currently being evaluated in a US Phase 2 intermediate dry AMD study.

Allegro is preparing to expand its anti-integrin portfolio into new ocular therapeutic areas.


Related Headlines